AstraZeneca, breast cancer and Daiichi Sankyo
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
If you suffered substantial losses and wish to serve as lead plaintiff of the AstraZeneca class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or ...
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
News Medical on MSN2d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina MakerMina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
AstraZeneca PLC AZN shares inched up 0.87% to £109.38 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 1.35% to 8,505.22.
Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for ...
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback